Trial Profile
A Phase 2a, Pilot, Open-Label Trial Evaluating the Safety, Tolerability and Pharmacodynamic Effects of GS-6624 in Subjects With Fibrosis of the Liver
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Simtuzumab (Primary)
- Indications Hepatic fibrosis
- Focus Adverse reactions
- Sponsors Novartis
- 01 Dec 2014 New trial record